ISSN:
1432-1041
Keywords:
Metformin
;
Glibenclamide
;
NIDDM
;
lipoproteins
;
C-peptide
;
diabetes mellitus
;
adverse effects
;
serum lipids
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary. Twenty-two NIDDM patients completed an open randomized cross-over study comparing metformin and glibenclamide over 1 year. The drugs had an equivalent effect on glycaemic control, but, in contrast to glibenclamide, metformin reduced body weight. Neither drug affected triglycerides, total-and LDL-cholesterol or C-peptide. Metformin caused a slight elevation of HDL-cholesterol (P 〈 0.05). No serious adverse effects were observed. The results show that oral hypoglycaemic agents are not associated with undesirable effects on lipids and lipoproteins.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00315441
Permalink
